Cargando…
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
Background: Adrenocortical carcinoma is a rare malignancy, with poor prognosis and limited treatment options for patients with advanced disease. Chemotherapy is the current standard first-line treatment, providing only a modest survival benefit. There is only limited treatment experience with immuno...
Autores principales: | Klein, Oliver, Senko, Clare, Carlino, Matteo S, Markman, Ben, Jackett, Louise, Gao, Bo, Lum, Caroline, Kee, Damien, Behren, Andreas, Palmer, Jodie, Cebon, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043165/ https://www.ncbi.nlm.nih.gov/pubmed/33889439 http://dx.doi.org/10.1080/2162402X.2021.1908771 |
Ejemplares similares
-
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
por: Klein, Oliver, et al.
Publicado: (2021) -
Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
por: Charles, Rebecca, et al.
Publicado: (2023) -
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
por: Taylor, Matthew, et al.
Publicado: (2015) -
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)